Citius pharmaceuticals, inc. secures $3.6 million through new jersey economic development program

Net operating losses converted into non-dilutive capital for ongoing r&d programs cranford, n.j., nov. 21, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the company has been selected to participate in new jersey's technology business tax certificate transfer (nol) program, more commonly known as the net operating loss (nol) program, and will receive $3.6 million in non-dilutive capital through the new jersey economic development authority (njeda).
CTXR Ratings Summary
CTXR Quant Ranking